Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Video content above is prompted by the following:

• Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.